Senaste nyheterna

Angelini Pharma and SK Biopharmaceuticals Announce Treatment of More Than 100,000 Patients Globally with Innovative Anti-Seizure Medication Cenobamate

Angelini Pharma and SK Biopharmaceuticals Announce Treatment of More Than 100,000 Patients Globally with Innovative Anti-Seizure Medication Cenobamate

Angelini Pharma and SK Biopharmaceuticals Co., Ltd., a global biotech focused on developing treatments for central nervous system (CNS) disorders and oncology, today announced that more than 100,000 patients1 have been treated globally with cenobamate, an innovative anti-seizure medication (ASM) developed by SK Biopharmaceuticals and its U.S. subsidiary SK Life Science.
New Headway Report highlights social impact of eco-anxiety, an emerging pre-traumatic mental health disorder

New Headway Report highlights social impact of eco-anxiety, an emerging pre-traumatic mental health disorder

- Key findings of the report highlight the ongoing toll that multiple parallel crises have on mental health in Europe, emphasizing the urgent need for individuals, communities, societies, and policymakers to improve mental well-being across the continent and foster a healthier and more resilient society for current and future generations
- Eco-anxiety, a pre-traumatic stress disorder where men

Angelini Pharma Presents Long-Term Data for cenobamate (ONTOZRY®) Demonstrating Sustained Benefit in Adults with Epilepsy Experiencing Uncontrolled Focal Seizures

Findings from a post-hoc analysis of the C017 open-label extension study demonstrated 23.6% of patients receiving adjuvant treatment with Cenobamate achieved sustained seizure freedom for at least one year.

Angelini Pharma and The European House – Ambrosetti’s Headway Epilepsy report shows up to 40% of European patients living with epilepsy are receiving inadequate treatment to control seizures

Angelini Pharma and The European House – Ambrosetti’s Headway Epilepsy report shows up to 40% of European patients living with epilepsy are receiving inadequate treatment to control seizures

Angelini Pharma and The European House – Ambrosetti, an Italian Think Tank, today announced the publication of the second edition of the “Headway – A new roadmap in Brain Health: Focus Epilepsy” report as part of an ongoing partnership aimed at sharing knowledge, raising awareness and promoting better health for people living with epilepsy in Europe.

Angelini Pharma and JCR Pharmaceuticals announce global collaboration for the development and commercialization of novel biologic therapies in epilepsy

Agreement gives Angelini Pharma the option to an exclusive license to develop and commercialize highly innovative brain-penetrant biologic therapeutics in epilepsy.

Angelini satsar inom hjärnhälsa – bryter ny mark

Angelini satsar inom hjärnhälsa – bryter ny mark

Angelini Pharma i Norden har en helhetssyn på vårdsektorn och menar att det inte bara är läkemedelsbehandling som gör skillnad ­– flera andra faktorer spelar också in. Läs hela artikeln om vad företaget gör inom hjärnhälsa!

Arvelle Therapeutics sätter fokus på svårbehandlad epilepsi

Arvelle Therapeutics sätter fokus på svårbehandlad epilepsi

Arvelle Therapeutics etablerades 2020 i Norden och ingår sedan februari i italienska internationella
Angelini Pharma Group, som genom förvärvet förstärker sin position inom CNS-området. Arvelle Therapeutics fokuserar på att patienter lokalt ska få tillgång till företagets läkemedel i ett tidigt skede. 

Kontakter

Haddy Jawara

Haddy Jawara

Presskontakt COMMUNICATION MANAGER NORDICS +46 76 946 94 12
Angelini Pharma Norden
Birger Jarlsgatan 6D
114 34 Stockholm
Sweden